Reproducibility of hippocampal atrophy rates measured with manual, FreeSurfer, AdaBoost, FSL/FIRST and the MAPS-HBSI methods in Alzheimer's disease

Document Details

Document Type
Pub Defense Publication
Publication Date
Jun 01, 2016
Source ID
10.1016/j.pscychresns.2016.04.006

Entities

People

  • Adriaan Versteeg
  • Alberto Redolfi
  • Baptiste Grenier
  • Bob W. Van Dijk
  • David Manset
  • Emma R. Mulder
  • Frederik Barkhof
  • Giovanni B. Frisoni
  • Hugo Vrenken
  • Jerome Revillard
  • Keith S. Cover
  • Kelvin K. Leung
  • Paolo Bosco
  • Peter J. Visser
  • Remko A. Jong
  • Ronald A. Van Schijndel
  • Soheil Damangir

Organizations

  • Alzheimer's Association
  • Alzheimer's Disease Neuroimaging Initiative
  • Alzheimer's Drug Discovery Foundation
  • BioClinica
  • Bristol-Myers Squibb
  • Canadian Institutes of Health Research
  • Chiron Corporation
  • Eisai (South Korea)
  • Eli Lilly and Company
  • GE HealthCare
  • Hoffmann-La Roche
  • Innogenetics
  • Johnson & Johnson Pharmaceutical Research and Development
  • Laboratoires Servier
  • Medpace
  • Merck & Co.
  • Meso Scale Diagnostics (United States)
  • National Institute of Biomedical Imaging and Bioengineering
  • National Institute on Aging
  • National Institutes of Health
  • Pfizer
  • Roche (United States)
  • Takeda Pharmaceutical Company
  • United States Department of Defense
  • VU University Medical Center